Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

A pilot open-label trial of minocycline in patients with autism and regressive features

Open access

Abstract

BACKGROUND: Minocycline is a tetracycline derivative that readily crosses the blood brain barrier and appears to have beneficial effects on neuroinflammation, microglial activation and neuroprotection in a variety of neurological disorders. Both microglial activation and neuroinflammation have been reported to be associated with autism. The study was designed to evaluate the effects of minocycline treatment on markers of neuroinflammation and autism symptomatology in children with autism and a history of developmental regression. METHODS: Eleven children were enrolled in an open-label trial of six months of minocycline (1.4 mg/kg). Ten children completed the trial. Behavioral measures were collected and cerebrospinal fluid (CSF), serum and plasma were obtained before and at the end of minocycline treatment and were analyzed for markers of neuroinflammation. RESULTS: Clinical improvements were negligible. The laboratory assays demonstrated significant changes in the expression profile of the truncated form of brain derived neurotrophic factor (BDNF) (P = 0.042) and hepatic growth factor (HGF) (P = 0.028) in CSF. In serum, the ratio of the truncated BDNF form and α-2 macroglobulin (α-2 M), was also significantly lower (P = 0.028) while the mature BDNF/α-2 M ratio revealed no difference following treatment. Only the chemokine CXCL8 (IL-8) was significantly different (P = 0.047) in serum while no significant changes were observed in CSF or serum in chemokines such as CCL2 (MCP-1) or cytokines such as TNF-α, CD40L, IL-6, IFN-γ and IL-1β when pre- and post-treatment levels of these proteins were compared. No significant pre- and post-treatment changes were seen in the profiles of plasma metalloproteinases, putative targets of the effects of minocycline. CONCLUSIONS: Changes in the pre- and post-treatment profiles of BDNF in CSF and blood, HGF in CSF and CXCL8 (IL-8) in serum, suggest that minocycline may have effects in the CNS by modulating the production of neurotrophic growth factors. However, in this small group of children, no clinical improvements were observed during or after the six months of minocycline administration. TRIAL REGISTRATION: NCT00409747.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1866-1955-5-9

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CXCL8 (IL-8) Post-treatment trend in serum. (A) Serum levels of CXCL8 (IL-8) were significantly lower after treatment with minocycline. (P = 0.047). (B) The trend profile of CXCL8 (IL-8) in serum showed a lowering effect of treatment in seven of ten patients (red lines) while only three of ten (green lines) showed an increase.
Figure 1 CXCL8 (IL-8) Post-treatment trend in serum. (A) Serum levels of CXCL8 (IL-8) were significantly lower after treatment with minocycline. (P = 0.047). (B) The trend profile of CXCL8 (IL-8) in serum showed a lowering effect of treatment in seven of ten patients (red lines) while only three of ten (green lines) showed an increase.CC BY · PubMed Central
Figure 2 Profiles of expression of brain derived neurotrophic factor in serum and cerebrospinal fluid. (A) Immunoblot analysis of brain derived neurotrophic factor (BDNF) isoforms in serum disclosed the presence of the pro-form (32 kD), truncated-form (28 kD) and mature form (14 kD) while plasma disclosed mostly the presence of the BDNF pro-form and truncated-form. The truncated-BDNF form was the only isoform seen in cerebrospinal fluid (CSF). (B)The BDNF truncated-form was significantly decreased after treatment with minocycline (P = 0.028) a trend that was observed in six of ten patients (red lines). (C) Although the mature form appeared to be decreased after treatment the difference pre- and post-treatment did not reach significance (P = 0.38). (D) BDNF in CSF measured by multiplexed array technique, which detects mostly the truncated-BNDF isoform, was significantly lowered after treatment (P = 0.042).
Figure 2 Profiles of expression of brain derived neurotrophic factor in serum and cerebrospinal fluid. (A) Immunoblot analysis of brain derived neurotrophic factor (BDNF) isoforms in serum disclosed the presence of the pro-form (32 kD), truncated-form (28 kD) and mature form (14 kD) while plasma disclosed mostly the presence of the BDNF pro-form and truncated-form. The truncated-BDNF form was the only isoform seen in cerebrospinal fluid (CSF). (B)The BDNF truncated-form was significantly decreased after treatment with minocycline (P = 0.028) a trend that was observed in six of ten patients (red lines). (C) Although the mature form appeared to be decreased after treatment the difference pre- and post-treatment did not reach significance (P = 0.38). (D) BDNF in CSF measured by multiplexed array technique, which detects mostly the truncated-BNDF isoform, was significantly lowered after treatment (P = 0.042).CC BY · PubMed Central
Figure 3 The levels of hepatic growth factor (HGF) in cerebrospinal fluid (CSF) were significantly increased following treatment with minocycline. (P = 0.028).
Figure 3 The levels of hepatic growth factor (HGF) in cerebrospinal fluid (CSF) were significantly increased following treatment with minocycline. (P = 0.028).CC BY · PubMed Central
Figure 4 A post-treatment lowering effect on MMP-7 was observed in seven of ten patients (red lines), but despite this trend it did not reach statistical significance. (P = 0.059).
Figure 4 A post-treatment lowering effect on MMP-7 was observed in seven of ten patients (red lines), but despite this trend it did not reach statistical significance. (P = 0.059).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 4

  1. Le Couteur A, Lord C, Rutter M: Autism Diagnostic Interview-Revised (ADI-R). 2003, Los Angeles: Western Psychological Services
  2. Mullen E: Infant Mullen Scales of Early Learning. 1995, Circle Pines, MN: American Guidance Service
  3. Elliott C: Manual for the Differential Ability Scales. 2007, San Antonio, TX: Pearson Assessments
  4. Guy W: ECDEU Assessment Manual of Psychopharmacology-Revised. 1976, Rockville, MD: Psychopharmacology Research Branch

Cited by

See all 60

Metadata

Authors
Pardo, C. A., Buckley, A., Thurm, A., Lee, L.-C., Azhagiri, A., Neville, D. M., & Swedo, S. E.
Affiliations
  • Johns Hopkins University (US)
  • National Institutes of Health (US)
Corresponding author
Pardo, Carlos A
Venue
Journal of Neurodevelopmental Disorders
Published
2013-04-08
Volume
5
Issue
1
Pages
9-9
ISSN
  • 1866-1947 (ISSN-L)
  • 1866-1955
OpenAlex
W2134333739
Cited by
58
References
47
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 3 · 2015: 4 · 2014: 7 · 2013: 1
FWCI
2.74
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/2.0 (tdm)
Locations
  • Journal of Neurodevelopmental Disorders (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Mental Health
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
minocycline, autism spectrum disorder, developmental regression, neuroinflammation, microglial activation, neuroprotection, brain-derived neurotrophic factor, hepatocyte growth factor, alpha2-macroglobulin, interleukin-8, cerebrospinal fluid biomarkers, children, tetracycline derivatives, metalloproteinases, cytokines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A pilot open-label trial of minocycline in patients with autism and regressive features. https://app.cochat.ai/papers/10.1186/1866-1955-5-9
The paper
Pardo, C. A., Buckley, A., Thurm, A., Lee, L.-C., Azhagiri, A., Neville, D. M., & Swedo, S. E. (2013). A pilot open-label trial of minocycline in patients with autism and regressive features. Journal of Neurodevelopmental Disorders. https://doi.org/10.1186/1866-1955-5-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.